FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
SOON-SHIONG PATRICK				Na	NantHealth, Inc. [NH]								,			
(Last) (First) (Middle)				3.]	3. Date of Earliest Transaction (MM/DD/YYYY)								X Director X 10% Owner X Officer (give title below) Other (specify below)			
C/O NANTHEALTH, INC., 760 FIRE TOWER RD, SUITE 107					8/28/2023								Chief Executive Officer			
(Street)					4. If Amendment, Date Original Filed (MM/DD/YYYY)							r) 6. Individu	6. Individual or Joint/Group Filing (Check Applicable Line)			
WINTERVILLE, NC 28590 (City) (State) (Zip)													Form filed by One Reporting Person X Form filed by More than One Reporting Person			
			Table I - N	on-Der	ivativ	e Securi	ities A	Acq	quired, Disj	osed	of, or E	eneficially Ov	ned			
1. Title of Security (Instr. 3) 2. Trans. Date			Exe	Deemed cution e, if any	(Instr. 8			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			7. Nature of Indirect Beneficial Ownership	
						Cod	e ·	V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock			8/28/202	23		P			15,384,616 (1)	A	\$0.	39		15,384,616	I	See Footnote (2)
Common Stock 8/28/				23		P			537,272 (1)	A	\$18.6125	(3)	15,921,888			See Footnote (2)
Common Stock													4,453,507 (4)(5)			See Footnote (5)
	Tab	le II - Der	ivative Sec	urities	Benef	icially O)wne	d (<i>e</i>	<i>e.g.</i> , puts, c	alls, w	varrant	s, options, con	vertible sec	urities)		
1. Title of Derivate Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date		3A. Deemed Execution Date, if any	4. Trans. (Instr. 8)	I Z	Derivative (Acquired (ADisposed or	Number of erivative Securities equired (A) or isposed of (D) astr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		Securi Deriva (Instr.	and Amount of ies Underlying tive Security 3 and 4)	Derivative Security (Instr. 5)	derivative Securities		(Instr. 4)	
				Code	v	(A)	(D))	Date I Exercisable I	Expiration Date		Amount or Number Shares	of	Transaction(s (Instr. 4)		

Explanation of Responses:

- (1) Shares of common stock, par value \$0.0001 per share ("Common Stock"), acquired from the issuer pursuant to a Stock Purchase Agreement (the "Purchase Agreement"), dated as of August 28, 2023, by and between the issuer and certain institutional and accredited investors, each as listed as signatories to the Purchase Agreement.
- (2) Shares held by Nant Capital, LLC ("Nant Capital"). California Capital Equity, LLC ("CalCap") directly owns all of the equity interests of Nant Capital and CalCap may be deemed to have beneficial ownership of the shares held by Nant Capital. Patrick Soon-Shiong directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
- (3) \$10,000,000 aggregate principal amount of the demand promissory note, dated January 4, 2016, as amended and restated on May 9, 2016 and April 27, 2021, respectively, by and between the issuer and Nant Capital (the "Subordinated Nant Capital Promissory Note"), were exchanged for shares of Common Stock in accordance with the terms and conditions of the Subordinated Nant Capital Promissory Note.
- (4) Includes (i) 4,147,469 shares of our common stock held by NantWorks, LLC; (ii) 193,426 shares of our common stock held by NantOmics, LLC; and (iii) 112,612 shares of our common stock held by Cambridge Equities, LP. NantWorks, LLC is the largest member of NantOmics, LLC, holding approximately 84% of the outstanding equity and approximately 99% of the outstanding voting equity. Dr. Patrick Soon-Shiong, is the controlling member of NantWorks, LLC with voting and dispositive power over the shares of the stock held by NantWorks, LLC. Dr. Patrick Soon-Shiong, indirectly owns all of the equity interests in NantWorks, LLC and Cambridge Equities, LP, and has voting and dispositive powers over the shares.

(5) On December 15, 2022, the issuer effected a 1-for-15 reverse stock split (the "Reverse Stock Split") of its outstanding shares of Common Stock. The numbers of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Split unless otherwise noted.

Reporting Owners

Reporting Owner Name / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
SOON-SHIONG PATRICK C/O NANTHEALTH, INC. 760 FIRE TOWER RD, SUITE 107 WINTERVILLE, NC 28590	X	X	Chief Executive Officer	•				
CALIFORNIA CAPITAL EQUITY, LLC C/O NANT CAPITAL, LLC 450 DULEY ROAD EL SEGUNDO, CA 90245		X						
NantWorks, LLC C/O NANT CAPITAL, LLC. 450 DULEY ROAD EL SEGUNDO, CA 90245		X						
Nant Capital, LLC 450 DULEY ROAD EL SEGUNDO, CA 90245		X						

Signatures

/s/ Charles Kenworthy, Manager, Nant Capital, LLC	8/30/2023	
**Signature of Reporting Person	Date	
/s/ Charles Kenworthy, Manager, California Capital Equity, LLC	8/30/2023	
**Signature of Reporting Person	Date	
/s/ Patrick Soon-Shiong	8/30/2023	
**Signature of Reporting Person	Date	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.